Is Incyte (INCY) a risky stock?
As of July 21, 2026, Clavix grades Incyte (INCY) B for risk, a composite score of 73 out of 100 on an A+ to F scale, which puts INCY in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind INCY's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how INCY scores on each, as of July 21, 2026.
What's moving INCY's risk right now
Company-specific signals Clavix flags behind INCY's current grade, drawn from recent news and filings as of July 21, 2026.
Long-term revenue growth and improving cash generation look positive, but falling returns on invested capital suggest recent spending hasn't paid off yet. Upcoming ESMO cancer-data presentations could draw attention, though no details were disclosed.
SEB Asset Management bought 646,168 INCY shares and Twin Capital bought 9,292 shares as new Q1 stakes. An SEC 8-K material-event filing was also posted on July 16, 2026.
Incyte gains access to Halozyme's ENHANZE drug-delivery technology for its INCA033989 program, with options on two more targets. Halozyme gets upfront cash now plus potential milestone and royalty payments later.
What a B grade means
On the Clavix A+ to F scale, INCY's composite of 73 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell INCY or any security. Grades are risk indicators, not predictions of return. Data may be delayed.